HeartBeam Expands Patent Portfolio with Innovative Cardiac Monitoring Technologies
TL;DR
With new U.S. patents, HeartBeam (NASDAQ: BEAT) strengthens its position in personalized cardiac care, setting itself apart from competitors.
HeartBeam's new patents cover a credit card-sized, cable-free 3D ECG device and a rhythm analysis algorithm for arrhythmia detection, enhancing its innovative cardiac monitoring technology.
HeartBeam's advancements in cardiac care technology promise to revolutionize patient care, enabling real-time monitoring and early detection of cardiac issues outside medical facilities for better health outcomes.
HeartBeam's cable-free 3D ECG device and rhythm analysis algorithm are paving the way for convenient and efficient cardiac monitoring, shaping the future of personalized healthcare.
Found this article helpful?
Share it with your network and spread the knowledge!
Medical technology company HeartBeam has strengthened its intellectual property portfolio with two new U.S. patents targeting innovative cardiac monitoring solutions. The patents cover a credit card-sized, cable-free 3D ECG device and a sophisticated rhythm analysis algorithm designed to improve cardiac health monitoring.
The first patent protects the company's compact ECG device capable of real-time cardiac monitoring and symptom capture. The second patent safeguards an advanced rhythm analysis algorithm that can detect arrhythmias by continuously analyzing cardiac signals and prompting users to collect additional 3D ECG data when anomalies are detected.
With these additions, HeartBeam now holds 20 issued patents and has 34 additional patents pending or approved. The expanded patent portfolio positions the company to advance its platform of portable cardiac monitoring technologies and prepare for upcoming FDA review of its 12-lead ECG synthesis software.
The new patents represent a significant step toward HeartBeam's goal of transforming cardiac care by enabling comprehensive heart health monitoring outside traditional medical facilities. By developing technologies that provide actionable cardiac insights wherever patients are located, the company aims to revolutionize how cardiac conditions are detected, monitored, and managed.
Curated from InvestorBrandNetwork (IBN)
